CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.29B, above the global median of $1.15B
- FinancialsAltman Z-Score 6.23: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
7.26%Above 5Y avg (5.22%)
Annual Rate
CNY 1.76Paid semi-annual
Payout Ratio
83.3%Moderate
Payback Period
17.8 yr
Last Ex-Dividend
Jun 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
15.38BCNY2.29B · vs all stocks (USD)
Trailing P/E
16.66xRevenue (TTM)
4.07BCNY605.48M · vs all stocks (USD)
Profit Margin
22.35%Beta
-0.0520xvs all stocks
52-Week Change
8.23%vs all stocks
Forward Annual Dividend Yield
7.26%vs all stocks
Market Capitalization
15.38BCNY2.29B · vs all stocks (USD)
Enterprise Value
14.79BCNY2.20B · vs all stocks (USD)
Trailing P/E
16.66xForward P/E
15.99xPEG Ratio
7.50xPrice to Sales (TTM)
3.74xPrice to Book (MRQ)
3.48xEnterprise to Revenue
3.63xEnterprise to EBITDA
12.58xGross Margin
68.13%Profit Margin
22.35%Operating Margin
31.95%Return on Assets (TTM)
9.26%Return on Equity (TTM)
20.26%Revenue (TTM)
4.07BCNY605.48M · vs all stocks (USD)
Revenue per Share (TTM)
6.44CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-12.50%Gross Profit (TTM)
2.66BCNY395.53M · vs all stocks (USD)
EBITDA (TTM)
1.19BCNY177.40M · vs all stocks (USD)
Net Income (TTM)
909.82MCNY135.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.10%Operating Cash Flow (TTM)
826.05MCNY122.84M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-280.34MCNY-41.69M · vs all stocks (USD)
Forward Annual Dividend Rate
1.76CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
7.26%vs all stocks
Trailing Annual Dividend Rate
1.38CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
5.69%vs all stocks
5-Year Average Dividend Yield
5.22%vs all stocks
Payout Ratio
83.33%Minority Interest (Equity)
680.29MCNYFY2025 · Dec 31, 2025Revenue
4.22BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.46BCNYFY2025 · Dec 31, 2025Gross Profit
2.76BCNYFY2025 · Dec 31, 2025Operating Income
1.12BCNY166.26M · vs all stocks (USD)
Pre-tax Income
1.21BCNYFY2025 · Dec 31, 2025Income Tax Expense
225.17MCNYFY2025 · Dec 31, 2025Net Income
987.55MCNYFY2025 · Dec 31, 2025EBIT
1.21BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.35BCNYFY2025 · Dec 31, 2025Research & Development
152.79MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.13BCNYFY2025 · Dec 31, 2025Other Operating Expenses
65.80MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
75.73MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.81MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.43CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.43CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
634.05MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
634.05MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
987.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-80.87MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.18BCNYFY2025 · Dec 31, 2025Free Cash Flow
904.00MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
709.06MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
987.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-71.49MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
256.19MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.22MCNYFY2025 · Dec 31, 2025Capital Expenditures
-280.48MCNYFY2025 · Dec 31, 2025Net Acquisitions
-48.85MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.81BCNYFY2025 · Dec 31, 2025Sale of Investments
1.71BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-426.33MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-777.95MCNYFY2025 · Dec 31, 2025Other Financing Charges
290.55MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-487.41MCNYFY2025 · Dec 31, 2025Shares Outstanding
635.61MSharesUpdated Aug 20, 2026Float Shares
352.99MSharesUpdated Aug 20, 2026% Held by Insiders
47.65%vs all stocks
% Held by Institutions
15.06%vs all stocks
Total Cash (MRQ)
938.47MCNY139.56M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.50CNYUpdated Aug 20, 2026Total Debt (MRQ)
1.82MCNY270.43K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0004xCurrent Ratio (MRQ)
1.86xBook Value per Share (MRQ)
6.89CNYUpdated Aug 20, 2026Total Assets
6.88BCNY1.02B · vs all stocks (USD)
Total Current Assets
3.43BCNYFY2025 · Dec 31, 2025Total Liabilities
2.18BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.45BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
272.15MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.91BCNYFY2025 · Dec 31, 2025Cash
708.13MCNYFY2025 · Dec 31, 2025Cash Equivalents
930.76KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
709.06MCNYFY2025 · Dec 31, 2025Other Short-term Investments
95.10MCNYFY2025 · Dec 31, 2025Accounts Receivable
404.90MCNYFY2025 · Dec 31, 2025Inventory
454.08MCNYFY2025 · Dec 31, 2025Accounts Payable
437.52MCNYFY2025 · Dec 31, 2025Short-term Debt
1.44MCNYFY2025 · Dec 31, 2025Other Current Liabilities
28.26MCNYFY2025 · Dec 31, 2025Long-term Debt
1.17MCNYFY2025 · Dec 31, 2025Common Stock (Book)
634.95MCNYFY2025 · Dec 31, 2025Retained Earnings
2.64BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.70BCNY699.40M · vs all stocks (USD)
Treasury Stock
84.63MCNYFY2025 · Dec 31, 202552-Week Low
21.05CNYUpdated Aug 20, 202652-Week High
27.83CNYUpdated Aug 20, 202652-Week Change
8.23%vs all stocks
Beta
-0.0520xvs all stocks
50-Day MA
24.49CNYUpdated Aug 20, 2026200-Day MA
24.39CNYUpdated Aug 20, 2026Avg 10-Day Volume
4.72MSharesUpdated Aug 20, 2026Avg 30-Day Volume
5.11MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.44CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.23: safe zoneNotable
Altman Z-Score: 6.23
High earnings qualityNotable
Earnings Quality Score: 0.63
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.29B, above the global median of $1.15BNotable
Market cap (USD): 2,287,343,693.745Global Median: 1,146,734,693.424
Revenue is $605.48M, above the global median of $520.53MNotable
Revenue (USD): 605,483,619.64Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hubei Jumpcan Pharmaceutical Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
CIE Automotive India Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Manhattan Associates Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities